Canada / Federal Consultations on a National Strategy for Rare Disease Drugs
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health…
‘Diversity of Members, Unity of Voice’
To be the unified Voice of Life Sciences in Ontario by representing the interests of the diverse life sciences community in the province through advocacy, education, facilitation of economic development and promotion of the industry locally, nationally and internationally.
LSO will be the single point of contact for Ontario’s life sciences stakeholders, not only for resolutions to public policy issues, but also to be the conduit between the many organizations in Ontario and our government partners. LSO will work in concert with life science stakeholders to grow the sector in Ontario and to improve our position in the global marketplace. LSO will promote the benefits of life science technologies and work to encourage their commercial success. LSO will continue to operate through the support of its membership and will continue to grow its value proposition to members, stakeholders and governments. LSO will seek to find alignment across our diverse community of life sciences stakeholders and work to complement and support their efforts through partnership and collaboration.
Life Sciences Ontario
109-1 Concorde Gate
Toronto, ON M3C 3N6
phone: 416-426-7293
fax: 416-426-7280
e-mail: admin@lifesciencesontario.ca
http://www.lifesciencesontario.ca/home/index.php
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health…
Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its…
As the only country in the world to boast a universal healthcare system that does not cover prescription drugs,…
The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt…
Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory…
Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for…
John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the…
Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a collaborative multi-stakeholder approach to…
Marina Vasiliou took the reins as managing director of Biogen Canada in November 2017 after a long and varied…
Diabetes Canada’s Jan Hux outlines how her organization has been able to shift from small, local programs to…
A new white paper from Fasken law firm asserts that the early filing of patents for innovative products is crucial…
Canada is the only developed country with a universal healthcare system that does not provide universal coverage of…